Deciphering INV3/t(3;3) myeloid leukemia vulnerabilities via proteogenomics and n-terminal proteomics
Active Project Grant Awarded Last action
- Award ID
- F31CA295026
- Recipient
-
University Of California, LOS Angeles UEI RN64EPNH8JC6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $180,628
Award facts
- Assistance listing
- 93.398 Cancer Research Manpower
- Completion date 71% complete
- Place of performance
- Los Angeles, CA 90095, USA
Award details come from USAspending.gov.
Description
- Abstract
- The overall objective of this proposal is to develop and apply novel proteogenomic approaches to identify therapeutic vulnerabilities of chromosome 3 rearranged myeloid leukemias. Chromosome 3 inversions or transversions (INV3/t(3;3)) leukemias result in aberrant overexpression of oncogenic transcription factor mecom (MDS1 and EVI1 complex locus, specifically a truncated isoform EVI1) and decreased expression of tumor suppressor GATA2. INV3/t(3;3) abnormal myeloid leukemia patients have no targeted precision therapies as they are resistant to standard of care regimens like tyrosine kinase inhibitors (tkis), and so experience dismal 5- year survival rates of
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $45,871 | |
| Amendment | $45,295 | |
| Amendment | $44,731 | |
| Amendment | $44,731 | |
| Original award | $0 |
Quick answers
Who received award F31CA295026?
F31CA295026 was awarded to University Of California, LOS Angeles by National Cancer Institute (National Institutes of Health) on December 1, 2024.
How much is award F31CA295026 worth?
$180,628 has been obligated on F31CA295026.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award